Zeposia(ozanimod)
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis and ulcerative colitis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3.
Download report
Favorite
FDA Novel Drug Approvals 2020
BMS
Commercial
Trade Name
FDA
EMA
Zeposia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ozanimod hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZEPOSIA | Celgene | N-209899 RX | 2020-03-25 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zeposia zeposia | New Drug Application | 2020-09-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | EFO_0003929 | D020529 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OZANIMOD HYDROCHLORIDE, ZEPOSIA, CELGENE INTL | |||
| 2025-03-25 | NCE | ||
| 2024-05-27 | I-860 | ||
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 2 | 5 | 1 | 2 | 9 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | 3 | — | 2 | 6 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | 5 | — | — | 6 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | 2 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | 1 | 10 | ||
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OZANIMOD |
| INN | ozanimod |
| Description | Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.
|
| Classification | Small molecule |
| Drug class | immunomodulators |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N |
Identifiers
| PDB | — |
| CAS-ID | 1306760-87-1 |
| RxCUI | 2288236 |
| ChEMBL ID | CHEMBL3707247 |
| ChEBI ID | — |
| PubChem CID | 52938427 |
| DrugBank | DB12612 |
| UNII ID | Z80293URPV (ChemIDplus, GSRS) |
Target
Agency Approved
S1PR1
S1PR1
S1PR5
S1PR5
Organism
Homo sapiens
Gene name
S1PR1
Gene synonyms
CHEDG1, EDG1
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 1
Protein synonyms
CD363, Endothelial differentiation G-protein coupled receptor 1, endothelial differentiation, sphingolipid G-protein-coupled receptor, 1, S1P receptor 1, S1P receptor Edg-1, Sphingosine 1-phosphate receptor Edg-1, sphingosine 1-phosphate receptor EDG1
Uniprot ID
Mouse ortholog
S1pr1 (13609)
sphingosine 1-phosphate receptor 1 (Q9R235)
Alternate
S1PR2
S1PR2
S1PR4
S1PR4
S1PR3
S1PR3
Organism
Homo sapiens
Gene name
S1PR2
Gene synonyms
EDG5
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 2
Protein synonyms
CTD-2369P2.2, deafness, autosomal recessive 68, Endothelial differentiation G-protein coupled receptor 5, endothelial differentiation, sphingolipid G-protein-coupled receptor, 5, S1P receptor 2, S1P receptor Edg-5, S1P receptor EDG5, Sphingosine 1-phosphate receptor Edg-5
Uniprot ID
Mouse ortholog
S1pr2 (14739)
sphingosine 1-phosphate receptor 2 (Q9R236)
Variants
Clinical Variant
No data
Financial
Zeposia - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,365 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more